DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 110.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,841 shares of the medical device company's stock after buying an additional 5,171 shares during the quarter. Lord Abbett & CO. LLC's holdings in DexCom were worth $765,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Kovitz Investment Group Partners LLC bought a new stake in DexCom in the 4th quarter worth approximately $1,925,000. Integrated Wealth Concepts LLC bought a new stake in shares of DexCom in the 4th quarter worth about $244,000. Banco Bilbao Vizcaya Argentaria S.A. lifted its holdings in shares of DexCom by 20.3% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 21,014 shares of the medical device company's stock valued at $1,635,000 after acquiring an additional 3,547 shares during the last quarter. J. Stern & Co. LLP grew its position in DexCom by 17.9% in the fourth quarter. J. Stern & Co. LLP now owns 27,625 shares of the medical device company's stock worth $2,148,000 after acquiring an additional 4,187 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in DexCom by 1.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 555,121 shares of the medical device company's stock valued at $43,172,000 after purchasing an additional 7,175 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,926 shares of company stock valued at $4,734,384. 0.32% of the stock is currently owned by insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM traded up $11.36 during midday trading on Friday, reaching $81.62. 10,689,391 shares of the company's stock traded hands, compared to its average volume of 4,248,687. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a fifty day simple moving average of $71.60 and a two-hundred day simple moving average of $76.67. The company has a market cap of $32.00 billion, a P/E ratio of 57.08, a PEG ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group boosted their target price on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday. Mizuho initiated coverage on shares of DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target on the stock. Robert W. Baird dropped their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday. Cfra Research raised DexCom to a "hold" rating in a research note on Friday, March 21st. Finally, Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.22.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.